ARTICLES BY ED MISETA

• COVID-19 & The Virtual Trial Rush: Front-Line Insights

  5/19/2020

  The COVID-19 pandemic caught many sponsor companies and sites unprepared. Clinical trial participants were told to stay home for their own safety and to relieve the burden on site personnel. For companies that had millions invested in trials that required data from those patients, panic set in and the rush was on for new technology solutions.

• MPI Research Breaks Ground On Imaging Center

  9/19/2013

  In June 2013 pharmaceutical research firm MPI Research formed a strategic partnership with imaging informatics provider INVICRO and 3D Imaging, a provider of radiopharmaceuticals. To date, the three companies have collaborated on over 100 unique imaging projects. The goal of the partnership was to unite molecular imaging, radiochemistry, and informatics under one roof, so as to accelerate the drug discovery and development process for drug sponsors. On September 6^th the three companies held a groundbreaking ceremony for a new world-class Imaging Center. The center is set to open in spring 2014, although many of the expanded imaging solutions, including nonhuman primate PET and CT imaging capabilities, became available in July 2013.

• Innovative Partnership Helps Shorten The ADC Supply Chain

  7/30/2013

  Ask anyone involved with antibody drug conjugates (ADCs), and they will tell you this is an exciting time to be in the market. While there are some concerns about possible regulatory guidance that will eventually be crafted to address this relatively new market, two recent FDA approvals (Adcetris and Kadcyla), and several more products in clinical trials has the future looking bright. Partnerships, such as the ones between Seattle Genetics and Spirogen, Celgene and  Sutro Biopharma, and the acquisition of MedImmune by AstraZeneca,  have been instrumental in advancing ADCs, and will continue to drive the technology going forward.